Community-acquired pneumonia (CAP) is one of the most common infections of infants and children in developing and industrialised countries. Given the clinical, social and economic importance of CAP for the paediatric age group, there is general agreement that a prompt and adequate therapeutic approach is essential in order to reduce the impact of the disease. However, there are various issues that make it difficult to establisharationalapproachtothetreatmentof paediatric CAP, including difficulty in identifying the aetiology ofthedisease,the emergence of resistance of the most frequent bacterial pathogens to commonly used antibiotics, and the lack of certain information about the possible preventive role of the recently marketed pneumococcal vaccine. More research is required in many areas, including the aetiological agents associated with CAP complications, the absence of a paediatric CAP severity score, a better definition of second-line antibiotic therapies, how to follow-up on patients with CAP, and the costeffectiveness of vaccines against respiratory pathogens.
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine